Signature Estate & Investment Advisors LLC Acquires 36,923 Shares of Eli Lilly and Company $LLY

Key Points

• Signature Estate & Investment Advisors LLC significantly increased its stake in Eli Lilly, acquiring an additional 36,923 shares, bringing its total holdings to 55,433 shares, worth approximately $43.2 million.
• Equity analysts are generally positive on Eli Lilly, with 14 buy ratings and a consensus price target of $939.12, despite recent target adjustments reflecting a range between $895.00 and $1,028.00.
• Eli Lilly reported an earnings per share (EPS) of $6.31 for the latest quarter, exceeding expectations and showing a substantial 37.6% year-over-year revenue growth to $15.56 billion.

Signature Estate & Investment Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 199.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,433 shares of the company's stock after acquiring an additional 36,923 shares during the period. Eli Lilly and Company accounts for 1.0% of Signature Estate & Investment Advisors LLC's holdings, making the stock its 23rd biggest position. Signature Estate & Investment Advisors LLC's holdings in Eli Lilly and Company were worth $43,212,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LLY. Hobbs Wealth Management LLC raised its holdings in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the period. Hixon Zuercher LLC grew its position in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the period. Ascent Capital Management LLC boosted its stake in Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the period. Finally, Cottage Street Advisors LLC boosted its stake in Eli Lilly and Company by 2.5% in the 1st quarter. Cottage Street Advisors LLC now owns 533 shares of the company's stock valued at $440,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Guggenheim reissued a "buy" rating and set a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday. Morgan Stanley cut their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research report on Friday, October 3rd. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the company an "overweight" rating in a report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $939.12.

Eli Lilly and Company Trading Down 1.9%

Shares of LLY stock opened at $803.53 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The stock's fifty day simple moving average is $753.09 and its 200 day simple moving average is $766.23. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $760.51 billion, a P/E ratio of 52.52, a P/E/G ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm posted $3.92 earnings per share. The business's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson acquired 200 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David A. Ricks bought 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.